Présentation de l'entreprise
Geron Corporation operates as a commercial-stage biopharmaceutical entity dedicated to the development of therapeutic products specifically targeting oncology. The company functions within the healthcare sector, more precisely classified under the biotechnology industry, an environment characterized by high research and development costs and significant regulatory scrutiny regarding novel drug approvals. In terms of scale, Geron Corporation holds a market capitalization of $1.10B while generating annual revenue of $183.88M and employing 258 individuals. These valuation and revenue figures indicate that the company maintains a mid-cap profile typical of specialized biotech firms that have advanced their product pipelines toward commercialization but have not yet achieved widespread profitability. The employee count of 258 suggests a lean operational structure focused on high-value scientific output rather than mass production, which is consistent with the early-to-mid stage development phase of its oncology therapeutics. The specific focus on adult patients with low- to intermediate-1 risk myelodysplastic syndromes via the RYTELO product underscores a niche market strategy aimed at addressing unmet medical needs in hematologic malignancies.
Santé financière
The company reported revenue of $183.88M over the trailing twelve months, yet it posted a net income of $-83,500,000 and an EBITDA of $-51,079,000. The substantial gap between the positive revenue and the negative net income reveals a cost structure dominated by non-operating expenses, likely including significant research and development costs or restructuring charges that outpace gross profit generation. Free cash flow stands at $-78,356,248, indicating that the company is currently burning cash to fund its operations and pipeline development, which limits immediate financial flexibility for shareholder returns or large-scale acquisitions. Regarding margins, the gross margin is an exceptional 97.4%, reflecting high pricing power or low cost of goods sold relative to revenue, while the operating margin of -17.7% and profit margin of -45.4% highlight the heavy burden of overhead and R&D spending before interest and taxes. The balance sheet shows $357.92M in cash compared to $121.99M in debt, resulting in a debt-to-equity ratio of 54.01, which suggests a leveraged position where debt significantly exceeds equity capitalization. Despite the high leverage, the current ratio of 4.66 indicates robust short-term liquidity, as the company holds ample current assets to cover its current liabilities with a comfortable margin of safety. Return on Equity is -33.0% and Return on Assets is -5.5%, metrics that reveal management is currently unable to generate positive returns on the capital employed due to the ongoing investment phase required to bring therapeutics to market.
Évaluation de la valorisation
The trailing twelve-month P/E ratio is listed as N/A due to negative earnings, whereas the forward P/E is calculated at 21.38, implying that the market expects significant earnings recovery or positive earnings in the future to justify the current price. The price-to-book ratio stands at 4.84, indicating that the market values the company's equity at nearly five times its book value, a premium often found in biotechnology firms where intangible assets like intellectual property are not fully captured on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 5.96 and an EV/EBITDA of -16.82, which suggests the company is valued based on its revenue generation potential rather than current profitability, as negative EBITDA renders the multiple less conventional for mature corporations. The 52-week high is $2.01 and the 52-week low is $1.04; without a specific current share price provided in the facts, the valuation relative to this range remains undefined, though the wide spread suggests potential for significant price movement based on pipeline milestones. The beta of 0.67 indicates that the stock exhibits lower volatility relative to the broader market, moving roughly two-thirds as much as the S&P 500, which offers a degree of stability uncommon for small-cap biotech stocks typically driven by binary clinical trial outcomes.
Growth & Income
Revenue growth year-over-year is recorded at 1.0%, while earnings growth is N/A due to the company's continued net losses; this disparity implies that top-line sales are stabilizing while profitability remains elusive, a common pattern during the scaling phase of commercializing a specialized oncology drug. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that it does not distribute cash to shareholders and instead retains all earnings to fund research, development, and working capital needs. The decision to forego dividends aligns with the cash burn rate of $-78,356,248, as the capital is required to sustain the clinical development of RYTELO and other assets in the oncology pipeline. Overall, the growth and income profile is characterized by modest revenue expansion and zero income distribution, prioritizing long-term asset building over immediate shareholder yield in a capital-intensive biotechnology sector.